Top of this page
Skip navigation, go straight to the content
Building the next generation biopharma leader
Discover how we are connecting patients, people and science in new ways to make breakthroughs in severe diseases
A global biopharma focused on severe diseases with operations in more than 40 countries and global revenue of €3.1 billion in 2009.

Roch Doliveux
UCB Chief Executive Officer